The Frontal Assessment Battery, known universally in neurology clinics as the FAB, was introduced in 2000 by Bruno Dubois and colleagues as a rapid bedside instrument for evaluating executive function—the family of mental abilities managed largely by the prefrontal cortex, including planning, inhibition, mental flexibility and the retrieval of words. The battery consists of six brief subtests: similarities, in which patients must identify abstract concepts shared by pairs of words; lexical fluency, in which they generate as many words as possible beginning with a given letter; motor series, a Luria-style sequencing task requiring the reproduction of a fist-edge-palm pattern; conflicting instructions, which demands that patients respond opposite to an examiner’s command; go-no-go, which measures impulse control; and prehension behavior, which probes for primitive grasping reflexes. Each subtest is scored out of three, giving a maximum of eighteen points. Because it is quick, cheap and requires no equipment, the FAB has been translated into dozens of languages and deployed across an extraordinary range of neurological conditions, from Parkinson’s disease to amyotrophic lateral sclerosis to Huntington’s disease.

The clinical problem the Italian team set out to address is one of the most persistent in dementia medicine. Alzheimer’s disease, the most common dementia, is classically a disorder of the temporal and parietal lobes, presenting first with memory loss for recent events. Behavioral variant frontotemporal dementia, or bvFTD, arises from degeneration of the frontal and anterior temporal lobes and announces itself not with forgetfulness but with a slow erosion of personality: disinhibition, apathy, compulsive behaviors, loss of empathy, dietary changes and poor judgment. In textbooks the two conditions look opposites, and the FAB was proposed early on as a discriminator—bvFTD patients were expected to collapse on frontal tests while Alzheimer’s patients, at least early on, would pass them. Yet real patients rarely read textbooks. Behaviorally disturbed patients can turn out to have Alzheimer’s pathology, and memory complaints can accompany frontotemporal degeneration. Several earlier studies, with smaller samples, came to conflicting conclusions about whether the FAB could separate the two diseases at all.

To resolve the question with adequate statistical power, the researchers assembled a retrospective cohort of 595 participants: 153 patients with Alzheimer’s disease whose diagnosis was supported by biomarkers—the fluid or imaging measures of amyloid and tau pathology that are now considered the biological gold standard—96 patients with probable bvFTD diagnosed under international consensus criteria, and 346 healthy controls, all of whom scored within the normal range on the Montreal Cognitive Assessment. This biomarker anchoring of the Alzheimer’s group is a methodological strength, since many previous studies relied on clinical diagnosis alone, a practice that can misclassify patients whose pathology does not match their symptoms. Disease severity in the patient groups was staged using Clinical Dementia Rating levels derived retrospectively from Mini-Mental State Examination scores, a validated mapping that allowed the team to ask a question rarely posed at this scale: does the FAB’s diagnostic value depend on how far the disease has progressed?

The analytical approach relied on receiver operating characteristic analysis, a statistical framework that evaluates a test by plotting its sensitivity against its specificity across all possible cutoff scores. The area under the resulting curve, or AUC, quantifies discriminatory accuracy on a scale from 0.5, equivalent to a coin flip, to 1.0, equivalent to perfect classification. Values between 0.7 and 0.8 are conventionally deemed adequate, 0.8 to 0.9 good, and above 0.9 excellent. The team calculated demographically adjusted FAB scores for every participant, then ran pairwise comparisons: each patient group against the healthy controls, and—critically—the two patient groups against each other, both as a whole and within severity strata. Complementary binary logistic regression models, adjusted for age and sex, were used to determine whether any individual subtest carried independent diagnostic information.

The first result was emphatic. In separating patients from healthy controls, the FAB performed excellently, confirming its value as a sensitive screen for the executive dysfunction that accompanies both Alzheimer’s disease and bvFTD. But the second result was sobering. When the comparison was restricted to patients only—Alzheimer’s versus bvFTD—the overall discriminatory accuracy was modest, falling well short of the thresholds clinicians would want before making a diagnosis on the basis of the test. The crucial twist was that this accuracy was not constant. Stratified by severity, the FAB distinguished the two diseases adequately only at the moderate-to-severe stages of dementia. In the earliest phases—patients with mild cognitive impairment or questionable dementia—the total score offered essentially no help in telling the two conditions apart.

The subtest analyses sharpened the picture further. Of the six components of the battery, only lexical fluency showed a statistically significant difference between the patient groups, with performance adjusted for demographic variables, and even that signal emerged specifically in patients at the earliest stage and in those at the moderate-to-severe stage. In the FAB’s lexical fluency task, patients must produce words beginning with a designated letter in sixty seconds, a task that loads heavily on left frontal-lobe systems governing strategic word retrieval and cognitive control over language output. Verbal fluency deficits have long been associated with frontotemporal degeneration, and prior FDG-PET imaging work has linked FAB performance in Alzheimer’s disease to frontal hypometabolism, but the new findings suggest that within this brief bedside battery, it is the fluency subtest alone—not the inhibition tasks, not the motor sequencing—that carries any differentiating weight between these two diagnoses. No significant differences emerged for any of the remaining five subtests.

The authors’ conclusion, stated with clinical candor, is that the FAB is an excellent screening test for executive dysfunction in both conditions but that its contribution to differential diagnosis emerges only at moderate-to-severe stages. The finding carries practical weight for clinicians and families alike. In real-world memory clinics, the moment of maximum diagnostic confusion is early in the illness, precisely when the FAB is least able to arbitrate. A first-degree relative watching a parent become uncharacteristically rude or passive wants an answer quickly; the new data indicate that a low FAB score confirms frontal impairment but cannot substitute for biomarker workup, structural imaging or multidisciplinary assessment when the question is which pathology is driving the change. Conversely, once dementia has progressed to a moderate or severe stage, the pattern of frontal test performance begins to align with the underlying disease in a way that can usefully support the clinical impression.

The study also adds to a growing body of evidence that the neat dichotomy between a “memory dementia” and a “behavior dementia” softens as both diseases advance. Neuroimaging studies have documented overlapping patterns of atrophy and white-matter deterioration in advanced Alzheimer’s and bvFTD, and recent biomarker-positive comparative studies have found the two conditions more alike in cognition and cortical thinning than their textbook portraits suggest. The prefrontal cortex, it appears, is not spared indefinitely in Alzheimer’s disease; as pathology spreads, executive dysfunction becomes the shared currency of both disorders, narrowing the behavioral and cognitive gap that a frontal bedside test is asked to detect.

For the field of dementia diagnostics, the results land amid an era of rapid change, with blood-based biomarkers and disease-modifying therapies reshaping early diagnosis. Yet brief cognitive instruments remain the first gate through which nearly every patient passes, and studies like this one—large, biomarker-anchored and severity-stratified—serve as essential calibration for what those instruments can and cannot promise. The FAB will continue to earn its place on the clinic cart as a sensitive detector of frontal-lobe dysfunction. What it will not do, the Milan consortium shows, is settle the Alzheimer’s-versus-bvFTD question early in the disease course, when that answer matters most.

The concept of using brain clocks offers a nuanced way to quantify how the brain ages across different environments, lifestyles, and disease states. Unlike simple calendar age, predicted brain age is calculated using complex models that evaluate brain structure and neural function, often through non-invasive imaging or electrophysiological techniques. The gap between predicted and actual age—the BAG—can indicate whether an individual’s brain is aging faster or slower than expected. Crucially, this measure also provides a window into the biological mechanisms that are affected in neurodegenerative diseases.

In this extensive study involving 1,399 participants from both the Global South and North, researchers employed electroencephalography (EEG) with source space connectivity analysis to delineate electrical network interactions across the brain. By coupling these functional insights with generative brain modeling, the study bridges the previously elusive gap between observable brain activity and the underlying biophysical health of neural circuits. This hybrid approach not only refines brain age predictions but also deepens understanding of how specific changes at a cellular and network level manifest as alterations in brain age.

One of the most striking findings of this study is the demonstration that brain age gaps are not uniform across populations. Factors such as geographic origin, socioeconomic status, sex, and educational background all bear significantly on the degree of accelerated aging. Specifically, individuals from lower-income regions in the Global South exhibited larger BAGs compared to those from wealthier Northern regions, suggesting that environmental burdens and systemic inequalities contribute to earlier and more pronounced brain aging. This dimension of diversity-sensitive brain clocks elevates the field towards more equitable and representative neuroscience, emphasizing the importance of context in brain health.

The study further identified sex as a crucial biological variable, with females showing greater brain age gaps than males, a trend that was particularly amplified in patients with Alzheimer’s disease. This finding aligns with growing evidence about sex differences in neurodegenerative disease prevalence and progression, inviting a reevaluation of how brain aging is approached in both research and clinical practice. Education also showed a protective relationship, where higher educational attainment correlated with smaller brain age gaps, underlining the cognitive reserve hypothesis which suggests that more education delays neurodegenerative decline.

Delving deeper into the physics of aging, the researchers applied rigorous biophysical modeling to parse out the neural mechanisms contributing to observed brain age gaps. In what stands as a significant advancement, they linked accelerated aging to a state of neural hyperexcitability combined with progressive structural disintegration. Hyperexcitability refers to an overactive neuronal state that can disrupt normal communication pathways, eventually leading to reduced efficiency and integrity within brain networks. This model suggests that in healthy aging, the brain experiences gradual wear resembling frayed wires: increased excitability and early-phase structural decay.

Conversely, the pathological acceleration seen in dementia, including Alzheimer’s disease and bvFTD, was distinguished by a transition into hypoexcitability alongside severe structural disintegration. Hypoexcitability, a dampened neural response, may reflect neuronal exhaustion or loss, which devastates the capacity for cognitive function and connectivity. The stark contrast between hyper- and hypoexcitability provides a mechanistic map that could explain why dementia is not merely an extension of normal aging but involves fundamentally different neuronal states and damage profiles.

This intricate understanding holds profound implications for future diagnostics and interventions. By pinpointing the excitability states associated with different aging trajectories, it may become possible to develop targeted therapeutics that modulate neural activity to slow or reverse brain age acceleration. Moreover, the structural integrity metrics embedded in their modeling can inform the design of biomarkers sensitive to even subtle deviations from healthy brain aging, facilitating earlier detection and personalized treatment strategies.

The diversity-sensitive angle of this research resonates with a crucial and often overlooked aspect of neuroscience — the need to incorporate global representation and social determinants into brain health models. Historically, most brain aging studies have focused on Western, high-income populations, a limitation that constrains the generalizability of findings. By integrating participants across socioeconomic and geographic spectra, this study not only broadens the scientific base but also exposes critical disparities that demand public health interventions sensitive to demographic realities.

Beyond population differences, the application of EEG source space connectivity as a core method represents a leap in the temporal and spatial resolution of brain age assessment. EEG, known for its millisecond-level timing, captures neural dynamics that other imaging modalities might miss. Coupled with innovative generative brain modeling, this approach unravels the latent biophysical parameters such as synaptic gain and connectivity strength, which underlie surface-level electrophysiological signals. The marriage of empirical data with computational models enriches interpretation and policy, transforming raw EEG signals into biologically meaningful markers.

The clinical implications are profound. Patients with Alzheimer’s disease not only had larger brain age gaps but also exhibited sex-specific exacerbations, suggesting that treatment and monitoring plans should account for gender as a pivotal factor. Similarly, bvFTD patients showed distinct patterns of hypoexcitability and network breakdown, highlighting the heterogeneity of neurodegenerative conditions and the necessity for disease-specific biomarker development.

In addition to advancing current understanding, this work sets a precedent for future research integrating multi-modal neuroimaging, socioeconomic data, and computational neuroscience. The holistic approach could potentially unravel complex interactions among genetics, environment, and brain physiology governing aging trajectories. It also opens avenues for exploring how lifestyle factors and interventions could potentially modulate neural excitability and network stability to promote healthier brain aging.

Furthermore, the association between education and reduced brain age gaps reinforces the value of lifelong cognitive engagement in mitigating neurodegeneration. This finding echoes decades of work on cognitive reserve but now extends into tangible biophysical mechanisms, providing a biological substrate that supports educational benefits. Policymakers and healthcare providers might harness such knowledge to advocate for inclusive education policies as a brain health investment.

The stark disparity between regions underscored by income-based brain aging differences serves as a potent reminder of the intersection between social justice and neuroscience. Brain health cannot be isolated from the broader context of inequality, nutrition, stress exposure, and healthcare access. Research like this builds a compelling case for integrative public health strategies that consider these social determinants as integral to combating dementia and aging-related brain disorders globally.

In summary, this study represents a landmark integration of diverse population data, advanced EEG connectivity analysis, and cutting-edge biophysical modeling to redefine brain age assessment and its relation to neurodegeneration. By illuminating the distinct excitability and structural profiles underlying healthy and pathological aging, and their interaction with socioeconomic and demographic variables, it pushes the frontiers of personalized brain health prediction. As brain clocks advance toward clinical utility, their responsiveness to diversity and underlying biophysics could revolutionize aging and dementia management.

The path ahead beckons further refinement of these computational models, larger cross-cultural cohorts, and intervention trials targeting neural excitability states. Success in these domains promises not only more accurate brain aging metrics but also novel frameworks for therapeutic development, public health policy, and ultimately, enhanced quality of life in an aging global population. This research underscores that the “time” measured by brain clocks is not just chronological but biophysical, social, and deeply human.

Subject of Research: Brain age prediction using EEG and biophysical modeling to understand aging and dementia mechanisms across diverse populations.

Article Title: Diversity-sensitive brain clocks linked to biophysical mechanisms in aging and dementia.

Article References:
Coronel-Oliveros, C., Moguilner, S., Hernandez, H. et al. Diversity-sensitive brain clocks linked to biophysical mechanisms in aging and dementia. Nat. Mental Health (2025). https://doi.org/10.1038/s44220-025-00502-7

Image Credits: AI Generated